Andersen J R, Lose G, Nørgaard M, Stimpel H, Andersen J T
Department of Surgery K, Frederiksberg Hospital, Copenhagen, Denmark.
Br J Urol. 1988 Apr;61(4):310-3. doi: 10.1111/j.1464-410x.1988.tb13964.x.
In a randomised, double-blind study, 20 women with idiopathic detrusor instability and associated symptoms were treated with terodiline 25 mg bd, placebo, and emepronium bromide 200 mg tds--each drug being given for 3 weeks with placebo as wash-out period before cross-over. The results were evaluated according to drug preference, frequency charts and elimination of detrusor instability on cystometry. Serum levels of both drugs were monitored as control of tablet intake. The preference for terodiline to placebo was statistically significant: 14/3 women (P less than 0.05), and the majority of women (12/4) preferred terodiline to emepronium. Terodiline also gave a small but significant reduction in 24 h micturition frequency and eliminated detrusor instability in almost 50% of the patients (P less than 0.05). Side effects were frequent but mild in all three treatment periods. It was concluded that terodiline offers an alternative in the treatment of female detrusor instability.
在一项随机双盲研究中，20名患有特发性逼尿肌不稳定及相关症状的女性，分别接受每日两次、每次25毫克的替地尔定治疗，服用安慰剂，以及每日三次、每次200毫克的溴化依米普明治疗——每种药物均服用3周，在交叉用药前以安慰剂作为洗脱期。根据药物偏好、排尿频率图表以及膀胱测压时逼尿肌不稳定的消除情况对结果进行评估。监测两种药物的血清水平以控制片剂摄入量。替地尔定相对于安慰剂的偏好具有统计学意义：14/3（P<0.05），并且大多数女性（12/4）更喜欢替地尔定而非溴化依米普明。替地尔定还使24小时排尿频率有小幅但显著的降低，并且在近50%的患者中消除了逼尿肌不稳定（P<0.05）。在所有三个治疗阶段，副作用都很常见但程度较轻。得出的结论是，替地尔定在治疗女性逼尿肌不稳定方面提供了一种替代方法。
